The estimated Net Worth of So Young Kwon is at least $289 dollars as of 8 August 2024. Ms Kwon owns over 213 units of Aptevo Therapeutics Inc stock worth over $289 and over the last 3 years she sold APVO stock worth over $0.
Ms has made over 6 trades of the Aptevo Therapeutics Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently she exercised 213 units of APVO stock worth $77 on 8 August 2024.
The largest trade she's ever made was exercising 9,375 units of Aptevo Therapeutics Inc stock on 8 August 2023 worth over $3,384. On average, Ms trades about 2,246 units every 52 days since 2021. As of 8 August 2024 she still owns at least 801 units of Aptevo Therapeutics Inc stock.
You can see the complete history of Ms Kwon stock trades at the bottom of the page.
SoYoung Kwon J.D., LL.M. is the Sr. VP, Gen. Counsel, Corp. Affairs & HR at Aptevo Therapeutics Inc.
So's mailing address filed with the SEC is 2401 4TH AVENUE, SUITE 1050, SEATTLE, WA, 98121.
Over the last 8 years, insiders at Aptevo Therapeutics Inc have traded over $17,157,676 worth of Aptevo Therapeutics Inc stock and bought 1,998,342 units worth $25,387,921 . The most active insiders traders include Kevin Ctang Capital Managem..., Fuad El Hibri et Daniel Abdun Nabi. On average, Aptevo Therapeutics Inc executives and independent directors trade stock every 38 days with the average trade being worth of $22,185. The most recent stock trade was executed by So Young Kwon on 8 August 2024, trading 213 units of APVO stock currently worth $77.
aptevo therapeutics is a biotech company primarily focused on bringing novel oncology and hematology therapeutics to market. we leverage the innovative adaptir™ platform technology, a unique approach to cancer immunotherapy, to improve outcomes for cancer patients. based in seattle, washington, the company is proud of its empowering work environment, entrepreneurial culture, and proprietary platform technology. as a result, aptevo has been able to attract some of the most innovative minds in the field. many of our team members have notable experience with other pioneering biotech companies including trubion, zymogenetics, immunex, dendreon, and vlst. at aptevo therapeutics, our core values of ownership and collaboration—combined with a history of innovation, dedication, and development—are positioning aptevo therapeutics to develop the science of what’s next in biotechnology.
Aptevo Therapeutics Inc executives and other stock owners filed with the SEC include: